DOCSLIB.ORG

― D04 - 1 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版（ 2019） カテゴリー別リスト

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

医学中央雑誌刊行会・医学用語シソーラス 第9版（ 2019） カテゴリー別リスト 多環式化合物 D04+ Spiro Compounds D04-10+ # Aplaviroc D04-10-10 # Buspirone D04-10-20 # Fenspiride D04-10-30 # Fluorescamine D04-10-40 # Fluoresceins D04-10-50+ # Eosin D04-10-50-10 # Eosine Bluish D04-10-50-20 # Erythrosine D04-10-50-30 # Fluorescein D04-10-50-40 # Fluorescein-5-isothiocyanate D04-10-50-50 # Rose Bengal D04-10-50-60 # Fluspirilene D04-10-60 # Ibutamoren D04-10-70 # Leucogenenol D04-10-80 # Nalfurafine D04-10-90 # Pazinaclone D04-10-100 # Prospidium D04-10-110 # Ranirestat D04-10-120 # Satavaptan D04-10-130 # Siramesine D04-10-140 # Spiperone D04-10-150 # Tiospirone D04-10-160 # * 縮合環式化合物 D04-20+ Steroids D04-20-10+ Androstanes D04-20-10-10+ Androstanols D04-20-10-10-10+ Androstane-3,17-diol D04-20-10-10-10-10 # Androsterone D04-20-10-10-10-20 # Dihydrotestosterone D04-20-10-10-10-30+ # Mestanolone D04-20-10-10-10-30-10 # Mesterolone D04-20-10-10-10-30-20 # Trilostane D04-20-10-10-10-30-30 # Drostanolone D04-20-10-10-10-40 # Epitiostanol D04-20-10-10-10-50 # Etiocholanolone D04-20-10-10-10-60 # Furazabol D04-20-10-10-10-70 # Mepitiostane D04-20-10-10-10-80 # Oxandrolone D04-20-10-10-10-90 # Oxymetholone D04-20-10-10-10-100 # Pancuronium D04-20-10-10-10-110 # Rocuronium Bromide D04-20-10-10-10-120 # Rostafuroxin D04-20-10-10-10-130 # Stanozolol D04-20-10-10-10-140 # Vecuronium Bromide D04-20-10-10-10-150+ # Rapacuronium Bromide D04-20-10-10-10-150-10 # Androstenes D04-20-10-10-20+ Abiraterone D04-20-10-10-20-10 # Androstadienes D04-20-10-10-20-20+ Epristeride D04-20-10-10-20-20-10 # Exemestane D04-20-10-10-20-20-20 # Fluticasone D04-20-10-10-20-20-30+ # * Fluticasone-Salmeterol D04-20-10-10-20-20-30-10 # Fluticasone Furoate D04-20-10-10-20-20-40 # Loteprednol D04-20-10-10-20-20-50 # Methandrostenolone D04-20-10-10-20-20-60 # Testolactone D04-20-10-10-20-20-70 # Androstatrienes D04-20-10-10-20-30 ― D04 - 1 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版（ 2019） カテゴリー別リスト Androstenedione D04-20-10-10-20-40+ # Atamestane D04-20-10-10-20-40-10 # Formestane D04-20-10-10-20-40-20 # Androstenols D04-20-10-10-20-50+ Androstenediols D04-20-10-10-20-50-10+ Androstenediol D04-20-10-10-20-50-10-10 # Fluoxymesterone D04-20-10-10-20-50-10-20 # Methandriol D04-20-10-10-20-50-10-30 # Cyanoketone D04-20-10-10-20-50-20 Dehydroepiandrosterone D04-20-10-10-20-50-30+ # Dehydroepiandrosterone Sulfate D04-20-10-10-20-50-30-10 # Testosterone D04-20-10-10-20-50-40+ # Boldenone D04-20-10-10-20-50-40-10 # Epitestosterone D04-20-10-10-20-50-40-20 # Hydroxytestosterones D04-20-10-10-20-50-40-30 Methenolone D04-20-10-10-20-50-40-40 # Methyltestosterone D04-20-10-10-20-50-40-50 # * Testosterone Enanthate D04-20-10-10-20-50-40-60 # Testosterone Propionate D04-20-10-10-20-50-40-70 # Drospirenone D04-20-10-10-20-60 # Finasteride D04-20-10-10-20-70 # Lapisteride D04-20-10-10-20-80 # Brominated Steroids D04-20-10-20 Cardanolides D04-20-10-30+ 強心配糖体 D04-20-10-30-10+ # Bufanolides D04-20-10-30-10-10+ # Proscillaridin D04-20-10-30-10-10-10 # Cardenolides D04-20-10-30-10-20+ Digitalis Glycosides D04-20-10-30-10-20-10+ # Digitonin D04-20-10-30-10-20-10-10 # Digitoxin D04-20-10-30-10-20-10-20+ # Acetyldigitoxins D04-20-10-30-10-20-10-20-10 # Digoxin D04-20-10-30-10-20-10-30+ # Acetyldigoxins D04-20-10-30-10-20-10-30-10 # Metildigoxin D04-20-10-30-10-20-10-30-20 # Lanatosides D04-20-10-30-10-20-10-40+ # Deslanoside D04-20-10-30-10-20-10-40-10 # Lanatoside C D04-20-10-30-10-20-10-40-20 # Digitoxin D04-20-10-30-10-20-20+ # Acetyldigitoxins D04-20-10-30-10-20-20-10 # Digitoxigenin D04-20-10-30-10-20-20-20 Digoxin D04-20-10-30-10-20-30+ # Acetyldigoxins D04-20-10-30-10-20-30-10 # Digoxigenin D04-20-10-30-10-20-30-20 Metildigoxin D04-20-10-30-10-20-30-30 # Strophanthins D04-20-10-30-10-20-40+ # Cymarine D04-20-10-30-10-20-40-10 # Ouabain D04-20-10-30-10-20-40-20 # Strophanthidin D04-20-10-30-10-20-40-30 Chlorinated Steroids D04-20-10-40+ Beclomethasone D04-20-10-40-10 # Chlormadinone Acetate D04-20-10-40-20+ # Osaterone D04-20-10-40-20-10 # Cyproterone D04-20-10-40-30+ # Cyproterone Acetate D04-20-10-40-30-10 # Cholanes D04-20-10-50+ Cholenes D04-20-10-50-10 Cholic Acids D04-20-10-50-20+ # Cholic Acid D04-20-10-50-20-10+ # ― D04 - 2 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版（ 2019） カテゴリー別リスト Cholates D04-20-10-50-20-10-10+ # Sodium Cholate D04-20-10-50-20-10-10-10 # Dehydrocholic Acid D04-20-10-50-20-20 # Deoxycholic Acid D04-20-10-50-20-30+ # Chenodeoxycholic Acid D04-20-10-50-20-30-10+ # Glycochenodeoxycholic Acid D04-20-10-50-20-30-10-10 # * Obeticholic Acid D04-20-10-50-20-30-10-20 # Taurochenodeoxycholic Acid D04-20-10-50-20-30-10-30 # Glycodeoxycholic Acid D04-20-10-50-20-30-20+ # Glycochenodeoxycholic Acid D04-20-10-50-20-30-20-10 # Taurodeoxycholic Acid D04-20-10-50-20-30-30+ # Taurochenodeoxycholic Acid D04-20-10-50-20-30-30-10 # Ursodeoxycholic Acid D04-20-10-50-20-30-40 # Glycocholic Acid D04-20-10-50-20-40+ # Glycodeoxycholic Acid D04-20-10-50-20-40-10+ # Glycochenodeoxycholic Acid D04-20-10-50-20-40-10-10 # Lithocholic Acid D04-20-10-50-20-50+ # Taurolithocholic Acid D04-20-10-50-20-50-10 # Taurocholic Acid D04-20-10-50-20-60+ # Taurodeoxycholic Acid D04-20-10-50-20-60-10+ # Taurochenodeoxycholic Acid D04-20-10-50-20-60-10-10 # Taurolithocholic Acid D04-20-10-50-20-60-20 # Cholestanes D04-20-10-60+ Cholestanols D04-20-10-60-10+ Cholestanol D04-20-10-60-10-10 # Squalamine D04-20-10-60-10-20 # Cholestanones D04-20-10-60-20 Cholestenes D04-20-10-60-30+ Cholecalciferol D04-20-10-60-30-10+ # Hydroxycholecalciferols D04-20-10-60-30-10-10+ # Alfacalcidol D04-20-10-60-30-10-10-10 # Calcifediol D04-20-10-60-30-10-10-20 # Dihydroxycholecalciferols D04-20-10-60-30-10-10-30+ # Calcitriol D04-20-10-60-30-10-10-30-10+ # Calcipotriol D04-20-10-60-30-10-10-30-10-10 # Falecalcitriol D04-20-10-60-30-10-10-30-10-20 # Maxacalcitol D04-20-10-60-30-10-10-30-10-30 # Seocalcitol D04-20-10-60-30-10-10-30-10-40 # 24,25-Dihydroxyvitamin D3 D04-20-10-60-30-10-10-30-20 # Tacalcitol D04-20-10-60-30-10-10-30-30 # Cholestadienes D04-20-10-60-30-20+ Cholestadienols D04-20-10-60-30-20-10+ Dehydrocholesterols D04-20-10-60-30-20-10-10 # Desmosterol D04-20-10-60-30-20-10-20 # Fusidic Acid D04-20-10-60-30-20-10-30 # Lanosterol D04-20-10-60-30-20-10-40 # Stigmasterol D04-20-10-60-30-20-10-50 # Cholestenones D04-20-10-60-30-30+ Ecdysteroids D04-20-10-60-30-30-10+ # Ecdysone D04-20-10-60-30-30-10-10 # Ecdysterone D04-20-10-60-30-30-10-20 # Ketocholesterols D04-20-10-60-30-30-20 # Cholesterol D04-20-10-60-30-40+ # Azacosterol D04-20-10-60-30-40-10 # Cholesterol Esters D04-20-10-60-30-40-20 # 19-Iodocholesterol D04-20-10-60-30-40-30 # * Oxysterols D04-20-10-60-30-40-40+ # Hydroxycholesterols D04-20-10-60-30-40-40-10 # Ketocholesterols D04-20-10-60-30-40-40-20 # ― D04 - 3 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版（ 2019） カテゴリー別リスト Remnant-Like Particle Cholesterol D04-20-10-60-30-40-50 # Ergocalciferols D04-20-10-60-30-50+ # Dihydrotachysterol D04-20-10-60-30-50-10 # Doxercalciferol D04-20-10-60-30-50-20 # 25-Hydroxyvitamin D2 D04-20-10-60-30-50-30 # Paricalcitol D04-20-10-60-30-50-40 # Ergosterol D04-20-10-60-30-60+ Withanolides D04-20-10-60-30-60-10 # Sitosterols D04-20-10-60-30-70 # Spirostans D04-20-10-60-40+ Diosgenin D04-20-10-60-40-10+ Solanine D04-20-10-60-40-10-10 # Sterols D04-20-10-60-50+ # Adosterol D04-20-10-60-50-10 # Cholecalciferol D04-20-10-60-50-20+ # Hydroxycholecalciferols D04-20-10-60-50-20-10+ # Alfacalcidol D04-20-10-60-50-20-10-10 # Calcifediol D04-20-10-60-50-20-10-20 # Dihydroxycholecalciferols D04-20-10-60-50-20-10-30+ # Calcitriol D04-20-10-60-50-20-10-30-10+ # Calcipotriol D04-20-10-60-50-20-10-30-10-10 # Falecalcitriol D04-20-10-60-50-20-10-30-10-20 # Maxacalcitol D04-20-10-60-50-20-10-30-10-30 # Seocalcitol D04-20-10-60-50-20-10-30-10-40 # 24,25-Dihydroxyvitamin D3 D04-20-10-60-50-20-10-30-20 # Tacalcitol D04-20-10-60-50-20-10-30-30 # Cholesterol D04-20-10-60-50-30+ # Azacosterol D04-20-10-60-50-30-10 # Cholestanol D04-20-10-60-50-30-20 # Cholesterol Esters D04-20-10-60-50-30-30 # Dehydrocholesterols D04-20-10-60-50-30-40+ # Desmosterol D04-20-10-60-50-30-40-10 # HDL Cholesterol D04-20-10-60-50-30-50 # 19-Iodocholesterol D04-20-10-60-50-30-60 # LDL Cholesterol D04-20-10-60-50-30-70 # * Oxysterols D04-20-10-60-50-30-80+ # Hydroxycholesterols D04-20-10-60-50-30-80-10 # Ketocholesterols D04-20-10-60-50-30-80-20 # Remnant-Like Particle Cholesterol D04-20-10-60-50-30-90 # VLDL Cholesterol D04-20-10-60-50-30-100 # 食品中のコレステロール D04-20-10-60-50-30-110 # Ergocalciferols D04-20-10-60-50-40+ # Dihydrotachysterol D04-20-10-60-50-40-10 # Doxercalciferol D04-20-10-60-50-40-20 # 25-Hydroxyvitamin D2 D04-20-10-60-50-40-30 # Paricalcitol D04-20-10-60-50-40-40 # Fusidic Acid D04-20-10-60-50-50 # Lanosterol D04-20-10-60-50-60 # Phytosterols D04-20-10-60-50-70+ # Brassinosteroids D04-20-10-60-50-70-10 # Ecdysteroids D04-20-10-60-50-70-20 # Sitosterols D04-20-10-60-50-70-30 # Stigmasterol D04-20-10-60-50-70-40 # Withanolides D04-20-10-60-50-70-50 # Solanine D04-20-10-60-50-80 # Trodusquemine D04-20-10-60-60 # Cyclosteroids D04-20-10-70 Estranes D04-20-10-80+ Estrenes D04-20-10-80-10+ ― D04 - 4 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版（ 2019） カテゴリー別リスト Allylestrenol D04-20-10-80-10-10 # Asoprisnil D04-20-10-80-10-20 # Epimestrol D04-20-10-80-10-30 # Equilenin D04-20-10-80-10-40 # Equilin D04-20-10-80-10-50 # Estradiol D04-20-10-80-10-60+ # Atrimustine D04-20-10-80-10-60-10 # Estradiol Benzoate D04-20-10-80-10-60-20 # Estradiol Undecylate D04-20-10-80-10-60-30 # Estradiol Valerate D04-20-10-80-10-60-40 # Estramustine D04-20-10-80-10-60-50 # Fulvestrant D04-20-10-80-10-60-60 # Oxabolone Cipionate D04-20-10-80-10-60-70
Recommended publications
  • Compositions Comprising Drospirenone Molecularly

    Compositions Comprising Drospirenone Molecularly

    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
  • The Effects of Targeted Deletion of the Aromatase Enzyme on Prostatic Contractile Responses to Noradrenaline in Mice

    The Effects of Targeted Deletion of the Aromatase Enzyme on Prostatic Contractile Responses to Noradrenaline in Mice

    495 The effects of targeted deletion of the aromatase enzyme on prostatic contractile responses to noradrenaline in mice Katherine T Gray, Jennifer L Short, Evan R Simpson1 and Sabatino Ventura Prostate Research Co-operative, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia 1Prince Henry’s Institute of Medical Research, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria 3168, Australia (Correspondence should be addressed to S Ventura; Email: [email protected]) Abstract This investigation aimed to see whether a change in the concentration-dependent contractions. Prazosin (0.3 mM) oestrogen to androgen ratio alters prostate contractility. Isolated attenuated the responses induced by noradrenaline and EFS in organ bath studies using prostates from aromatase knockout all mice (P%0.019, nZ5–7), while cocaine (10 mM) attenuated (ArKO) mice which were homozygous (ArKOK/K)and the responses evoked by tyramine (P!0.001, nZ6). There were heterozygous (ArKOC/K) for the disrupted aromatase cyp19 no genotype differences in EFS- and noradrenaline-induced gene and wild-type littermates (ArKOC/C) were conducted. responses (PR0.506, nZ10–13). Prostates from ArKOK/K The distribution of noradrenergic nerves was visualized using and ArKOC/K mice were more sensitive to tyramine than the sucrose–potassium phosphate–glyoxylic acid method. prostates from ArKOC/C mice (P!0.001, nZ11–13). Dense ArKOK/K mice had increased prostate weights compared adrenergic innervation of the prostate was similar in all mice. with ArKOC/C mice. Frequency–response curves to electrical These results suggest that although the absence of aromatase field stimulation (EFS; 0.5 ms pulse duration, 60 V,0.1–20 Hz) increases prostatic growth, this translates only to a subtle and yielded frequency-dependent contractions, while noradrenaline selective increase in contractility in mature mice.
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
  • 2020 Kansas Statutes

    2020 Kansas Statutes

    2020 Kansas Statutes 65-4105. Substances included in schedule I. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide) 9821 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide) 9815 (3) Acetylmethadol 9601 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551 (6) Allylprodine 9602 (7) Alphacetylmethadol 9603(except levo-alphacetylmethadol also known as levo- alpha-acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine 9604 (9) Alphamethadol 9605 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) 9814 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide) 9832 (12) Benzethidine 9606 (13) Betacetylmethadol 9607 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide) 9830 (15) Beta-hydroxy-3-methylfentanyl (other
  • Summary of Product Characteristics

    Summary of Product Characteristics

    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Aldactone 50 mg Film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg of Spironolactone. For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet (Tablets) Round, white coloured, biconvex tablet with a peppermint odour embossed ‘SEARLE over 916’ on one side and the other side plain. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. Children should only be treated under guidance of a paediatric specialist. There is limited paediatric data available (see sections 5.1 and 5.2). 4.2 Posology and method of administration Administration of Aldactone once daily with a meal is recommended. Posology Adults Congestive heart failure: Usual dose - 100 mg/day. In difficult or severe cases the dosage may be gradually increased up to 200 mg/day. When oedema is controlled, the usual maintenance level is 75 mg/day to 200 mg/day. Severe heart failure in conjunction with standard therapy (New York Heart Association Class III-IV): Based on the Randomized Aldactone Evaluation Study (RALES), treatment in conjunction with standard therapy should be initiated at a dose of spironolactone 25 mg once daily in patients with a serum potassium ≤5.0 mEq/L and serum creatinine ≤2.5 mg/dL. Patients who tolerate 25 mg once daily may have their dose increased to 50 mg once daily as clinically indicated.
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )

    ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )

    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
  • Supplementary Information

    Supplementary Information

    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Targeting Multidrug Resistance Proteins and C-Type Natriuretic Peptide to Optimise Cyclic GMP Signalling in Cardiovascular Disease

    Targeting Multidrug Resistance Proteins and C-Type Natriuretic Peptide to Optimise Cyclic GMP Signalling in Cardiovascular Disease

    Targeting multidrug resistance proteins and C-type natriuretic peptide to optimise cyclic GMP signalling in cardiovascular disease Robert Matthew Henry Grange Submitted in partial fulfilment of the requirements of the Degree of Doctor of Philosophy Heart Centre William Harvey Research Institute Barts & The London School of Medicine & Dentistry Queen Mary University of London Charterhouse Square London EC1M 6BQ United Kingdom STATEMENT OF ORIGINALITY I, Robert Matthew Henry Grange, confirm that the research included within this thesis is my own work or that where it has been carried out in collaboration with, or supported by others, that this is duly acknowledged below and my contribution indicated. Previously published material is also acknowledged below. I attest that I have exercised reasonable care to ensure that the work is original, and does not to the best of my knowledge break any UK law, infringe any third party’s copyright or other Intellectual Property Right, or contain any confidential material. I accept that the College has the right to use plagiarism detection software to check the electronic version of the thesis. I confirm that this thesis has not been previously submitted for the award of a degree by this or any other university. The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author. Signature: Date: 05/05/2016 I PUBLISHED ABSTRACTS Allen RMH, Renukanthan A, Bubb KJ, Villar IC, Moyes AJ, Baliga RS, Hobbs AJ. Investigation of the role of multidrug resistance proteins (MRPs) in vascular homeostasis.
  • A10 Anabolic Steroids Hardcore Info

    A10 Anabolic Steroids Hardcore Info

    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
  • The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral

    The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral

    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral 2 replication-transcription complex in culture cells 3 4 Shutoku Matsuyamaa#, Miyuki Kawasea, Naganori Naoa, Kazuya Shiratoa, Makoto Ujikeb, Wataru 5 Kamitanic, Masayuki Shimojimad, and Shuetsu Fukushid 6 7 aDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan 8 bFaculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan 9 cDepartment of Infectious Diseases and Host Defense, Gunma University Graduate School of 10 Medicine, Gunma, Japan 11 dDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 12 13 Running Head: Ciclesonide blocks SARS-CoV-2 replication 14 15 #Address correspondence to Shutoku Matsuyama, [email protected] 16 17 Word count: Abstract 149, Text 3,016 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 We screened steroid compounds to obtain a drug expected to block host inflammatory responses and 20 MERS-CoV replication. Ciclesonide, an inhaled corticosteroid, suppressed replication of MERS-CoV 21 and other coronaviruses, including SARS-CoV-2, the cause of COVID-19, in cultured cells. The 22 effective concentration (EC90) of ciclesonide for SARS-CoV-2 in differentiated human bronchial 23 tracheal epithelial cells was 0.55 μM.
  • 2010 Prohibited List

    2010 Prohibited List

    The World Anti-Doping Code THE 2010 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2010 The Prohibited List 2010 19 September 2009 THE 2010 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2010 All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2.1 to S2.5, S.4.4 and S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone